ReviewBreast cancer research : BCR2001
Syk: a new player in the field of breast cancer.
Review in Breast cancer research : BCR, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges.Frontiers in pharmacology · 2023Review
- [Spleen tyrosine kinase inhibits proliferation and promotes apoptosis of colorectal cancer cells in vitro via regulating Fra-1].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2017Article
- Insights into the allosteric regulation of Syk association with receptor ITAM, a multi-state equilibrium.Physical chemistry chemical physics : PCCP · 2016Article
- Novel SYK gene variations and changes in binding sites of miRs in breast cancer patients.Cancer biomarkers : section A of Disease markers · 2016Article
- Molecular cloning, expression pattern, and molecular evolution of the spleen tyrosine kinase in lamprey, Lampetra japonica.Development genes and evolution · 2015Article
- Hypermethylation and prognostic implication of Syk gene in human colorectal cancer.Medical oncology (Northwood, London, England) · 2013Article
- The promoter methylation of the Syk gene in nasopharyngeal carcinoma cell lines.Oncology letters · 2012Article
- Identification of novel SNPs in SYK gene of breast cancer patients: computational analysis of SNPs in the 5'UTR.Molecular biology reports · 2012Article
- Article
- Delocalization of gamma-tubulin due to increased solubility in human breast cancer cell lines.Cancer biology & therapy · 2010Article
- Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.Leukemia · 2006Article
- SYK expression in human breast cancer.Journal of carcinogenesis · 2005Article
- Hypermethylation of Syk gene in promoter region associated with oncogenesis and metastasis of gastric carcinoma.World journal of gastroenterology · 2004Article
- Overexpression of leukocyte marker CD43 causes activation of the tumor suppressor proteins p53 and ARF.Oncogene · 2004Article
- Hypermethylation of the spleen tyrosine kinase promoter in T-lineage acute lymphoblastic leukemia.Oncogene · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast tumor development and progression are thought to occur through a complex, multistep process, including oncogene activation (eg HER2/neu) and mutation or loss of tumor suppressor genes (eg p53). Determining the function of genetic alterations in breast carcinoma tumorigenesis and metastasis has been the focus of intensive research efforts for several decades. One group of proteins that play a critical role in breast cancer cell signaling pathways are tyrosine kinases. Overexpression of the tyrosine kinase HER2/neu is observed in many human breast cancers and is positively correlated with enhanced tumorigenesis. Recently, another tyrosine kinase, Syk, has been implicated as an important inhibitor of breast cancer cell growth and metastasis. This recent finding was unexpected, since Syk function has been predominantly linked to hematopoietic cell signaling, and is discussed further in this commentary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.